Since current G12C inhibitors are less active in colorectal or pancreatic cancers [19, 54], we also tested the combination of FTis and KRAS-G12C inhibitors on pancreatic and colorectal adenocarcinoma cells. This evidence concerns the gene KRAS and pancreatic neoplasm.